Home LiteratureArticle Details
PMID: 10995470 Published · ppublish English Journal Article

Position-specific trapping of topoisomerase I-DNA cleavage complexes by intercalated benzo[a]- pyrene diol epoxide adducts at the 6-amino group of adenine.

Pommier Y, Laco GS, Kohlhagen G, Sayer JM, Kroth H, Jerina DM

Abstract

DNA topoisomerase I (top1) is the target of potent anticancer agents, including camptothecins and DNA intercalators, which reversibly stabilize (trap) top1 catalytic intermediates (cleavage complexes). The aim of the present study was to define the structural relationship between the site(s) of covalently bound intercalating agents, whose solution conformations in DNA are known, and the site(s) of top1 cleavage. Two diastereomeric pairs of oligonucleotide 22-mers, derived from a sequence used to determine the crystal structure of top1-DNA complexes, were synthesized. One pair contained either a trans-opened 10R- or 10S-benzo[a]pyrene 7, 8-diol 9,10-epoxide adduct at the N(6)-amino group of a central 2'-deoxyadenosine residue in the scissile strand, and the other pair contained the same two adducts in the nonscissile strand. These adducts were derived from the (+)-(7R,8S,9S,10R)- and (-)-(7S,8R,9R, 10S)-7,8-diol 9,10-epoxides in which the benzylic 7-hydroxyl group and the epoxide oxygen are trans. On the basis of analogy with known solution conformations of duplex oligonucleotides containing these adducts, we conclude that top1 cleavage complexes are trapped when the hydrocarbon adduct is intercalated between the base pairs flanking a preexisting top1 cleavage site, or between the base pairs immediately downstream (3' relative to the scissile strand) from this site. We propose a model with the +1 base rotated out of the duplex, and in which the intercalated adduct prevents religation of the corresponding nucleotide at the 5' end of the cleaved DNA. These results suggest mechanisms whereby intercalating agents interfere with the normal function of human top1.

MeSH Terms
Adenine/chemistry,metabolism Benzopyrenes/chemistry,metabolism DNA/chemistry,metabolism DNA Topoisomerases, Type I/chemistry,metabolism Epoxy Compounds/chemistry,metabolism Humans Recombinant Proteins/chemistry,metabolism Structure-Activity Relationship Substrate Specificity
Chemicals
Benzopyrenes Epoxy Compounds Recombinant Proteins DNA DNA Topoisomerases, Type I Adenine
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Pommier Y
Laboratory of Molecular Pharmacology, Division of Basic Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. pommier@nih.gov
Laco G S
Kohlhagen G
Sayer J M
Kroth H
Jerina D M
References (43)
43 references, click to expand
  1. Crystal structure of a thwarted mismatch glycosylase DNA repair complex.
    EMBO J. 1999 Dec 1;18(23):6599-609 PMID: 10581234
  2. Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin.
    Cancer Res. 1989 Nov 15;49(22):6318-23 PMID: 2553253
  3. Minimal DNA duplex requirements for topoisomerase I-mediated cleavage in vitro.
    J Biol Chem. 1990 Jul 25;265(21):12529-35 PMID: 2165067
  4. Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin.
    Nucleic Acids Res. 1990 Nov 25;18(22):6611-9 PMID: 2174543
  5. Stereoselective release of polycyclic aromatic hydrocarbon-deoxyadenosine adducts from DNA by the 32P postlabeling and deoxyribonuclease I/snake venom phosphodiesterase digestion methods.
    Chem Res Toxicol. 1990 Nov-Dec;3(6):545-50 PMID: 1966469
  6. Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin.
    J Biol Chem. 1991 Oct 25;266(30):20418-23 PMID: 1657924
  7. Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide.
    Nucleic Acids Res. 1991 Nov 11;19(21):5973-80 PMID: 1658748
  8. DNA adducts from carcinogenic and noncarcinogenic enantiomers of benzo[a]pyrene dihydrodiol epoxide.
    Chem Res Toxicol. 1989 Sep-Oct;2(5):334-40 PMID: 2519824
  9. Characterization of an altered DNA catalysis of a camptothecin-resistant eukaryotic topoisomerase I.
    Nucleic Acids Res. 1993 Feb 11;21(3):593-600 PMID: 8382801
  10. Translesional synthesis on a DNA template containing a single stereoisomer of dG-(+)- or dG-(-)-anti-BPDE (7,8-dihydroxy-anti-9,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene).
    Biochemistry. 1993 Jul 27;32(29):7531-41 PMID: 8338850
  11. Specific interaction of camptothecin, a topoisomerase I inhibitor, with guanine residues of DNA detected by photoactivation at 365 nm.
    Biochemistry. 1993 Aug 31;32(34):8955-62 PMID: 8395887
  12. Solution conformation of the (+)-trans-anti-[BPh]dA adduct opposite dT in a DNA duplex: intercalation of the covalently attached benzo[c]phenanthrene to the 5'-side of the adduct site without disruption of the modified base pair.
    Biochemistry. 1993 Nov 23;32(46):12488-97 PMID: 8241140
  13. Induction of cleavage in topoisomerase I c-DNA by topoisomerase I enzymes from calf thymus and wheat germ in the presence and absence of camptothecin.
    Nucleic Acids Res. 1993 Nov 11;21(22):5157-66 PMID: 8255771
  14. Characterization of intra- and intermolecular DNA ligation mediated by eukaryotic topoisomerase I. Role of bipartite DNA interaction in the ligation process.
    J Biol Chem. 1994 Jan 7;269(1):721-9 PMID: 8276874
  15. Induction of reversible complexes between eukaryotic DNA topoisomerase I and DNA-containing oxidative base damages. 7, 8-dihydro-8-oxoguanine and 5-hydroxycytosine.
    J Biol Chem. 1999 Mar 26;274(13):8516-23 PMID: 10085084
  16. HhaI methyltransferase flips its target base out of the DNA helix.
    Cell. 1994 Jan 28;76(2):357-69 PMID: 8293469
  17. Solution conformation of the (-)-trans-anti-benzo[c]phenanthrene-dA ([BPh]dA) adduct opposite dT in a DNA duplex: intercalation of the covalently attached benzo[c]phenanthrenyl ring to the 3'-side of the adduct site and comparison with the (+)-trans-anti-[BPh]dA opposite dT stereoisomer.
    Biochemistry. 1995 Jan 31;34(4):1295-307 PMID: 7827077
  18. NMR solution structure of a nonanucleotide duplex with a dG mismatch opposite a 10R adduct derived from trans addition of a deoxyadenosine N6-amino group to (-)-(7S,8R,9R,10S)-7,8-dihydroxy-9,10-epoxy-7,8,9,10- tetrahydrobenzo[a]pyrene.
    Biochemistry. 1995 Jan 31;34(4):1364-75 PMID: 7827084
  19. In vivo and in vitro replication consequences of stereoisomeric benzo[a]pyrene-7,8-dihydrodiol 9,10-epoxide adducts on adenine N6 at the second position of N-ras codon 61.
    J Biol Chem. 1995 Mar 10;270(10):4990-5000 PMID: 7890605
  20. Nuclear magnetic resonance solution structure of an undecanucleotide duplex with a complementary thymidine base opposite a 10R adduct derived from trans addition of a deoxyadenosine N6-amino group to (-)-(7R,8S,9R,10S)-7,8-dihydroxy- 9,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene.
    Biochemistry. 1995 Jul 18;34(28):9009-20 PMID: 7619800
  21. Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites.
    Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8861-5 PMID: 7568032
  22. NMR solution structure of a nonanucleotide duplex with a dG mismatch opposite a 10S adduct derived from trans addition of a deoxyadenosine N6-amino group to (+)-(7R,8S,9S,10R)-7,8-dihydroxy-9,10-epoxy-7,8,9,10- tetrahydrobenzo[a]pyrene: an unusual syn glycosidic torsion angle at the modified dA.
    Biochemistry. 1995 Oct 17;34(41):13570-81 PMID: 7577946
  23. DNA recombinase activity of eukaryotic DNA topoisomerase I; effects of camptothecin and other inhibitors.
    Mutat Res. 1995 Sep;337(2):135-45 PMID: 7565862
  24. Adduction of the human N-ras codon 61 sequence with (-)-(7S,8R,9R,10S)-7,8-dihydroxy-9,10-epoxy-7,8,9,10-tetrahydrobenzo[a] pyrene: structural refinement of the intercalated SRSR(61,2) (-)-(7S,8R,9S,10R)-N6-[10-(7,8,9,10- tetrahydrobenzo[a]pyrenyl)]-2'-deoxyadenosyl adduct from 1H NMR.
    Biochemistry. 1996 May 21;35(20):6212-24 PMID: 8639561
  25. DNA topoisomerases.
    Annu Rev Biochem. 1996;65:635-92 PMID: 8811192
  26. Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA.
    Mol Pharmacol. 1996 Nov;50(5):1095-102 PMID: 8913340
  27. NMR solution structures of stereoisometric covalent polycyclic aromatic carcinogen-DNA adduct: principles, patterns, and diversity.
    Chem Res Toxicol. 1997 Feb;10(2):111-46 PMID: 9049424
  28. Effects of uracil incorporation, DNA mismatches, and abasic sites on cleavage and religation activities of mammalian topoisomerase I.
    J Biol Chem. 1997 Mar 21;272(12):7792-6 PMID: 9065442
  29. Crystal structure of the breakage-reunion domain of DNA gyrase.
    Nature. 1997 Aug 28;388(6645):903-6 PMID: 9278055
  30. Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA.
    Science. 1998 Mar 6;279(5356):1504-13 PMID: 9488644
  31. A model for the mechanism of human topoisomerase I.
    Science. 1998 Mar 6;279(5356):1534-41 PMID: 9488652
  32. Conservation of structure and mechanism between eukaryotic topoisomerase I and site-specific recombinases.
    Cell. 1998 Mar 20;92(6):841-50 PMID: 9529259
  33. Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin.
    J Med Chem. 1998 Jun 18;41(13):2216-26 PMID: 9632354
  34. Sequence context profoundly influences the mutagenic potency of trans-opened benzo[a]pyrene 7,8-diol 9,10-epoxide-purine nucleoside adducts in site-specific mutation studies.
    Biochemistry. 1998 Jun 23;37(25):9127-37 PMID: 9636059
  35. Structure of DNA topoisomerases.
    Biochim Biophys Acta. 1998 Oct 1;1400(1-3):3-18 PMID: 9748476
  36. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme.
    Biochim Biophys Acta. 1998 Oct 1;1400(1-3):83-105 PMID: 9748515
  37. DNA sequence selectivity of topoisomerases and topoisomerase poisons.
    Biochim Biophys Acta. 1998 Oct 1;1400(1-3):185-94 PMID: 9748568
  38. Multiple conformations of an intercalated (-)-(7S,8R,9S, 10R)-N6-[10-(7,8,9,10-tetrahydrobenzo[a]pyrenyl)]-2'-deoxyadenosyl adduct in the N-ras codon 61 sequence.
    Biochemistry. 1998 Nov 24;37(47):16516-28 PMID: 9843418
  39. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II.
    J Biol Chem. 1984 Nov 10;259(21):13560-6 PMID: 6092381
  40. A high affinity topoisomerase I binding sequence is clustered at DNAase I hypersensitive sites in Tetrahymena R-chromatin.
    Cell. 1985 Jun;41(2):541-51 PMID: 2985282
  41. Characterization of a camptothecin-resistant human DNA topoisomerase I.
    J Biol Chem. 1988 Mar 15;263(8):3912-6 PMID: 2831213
  42. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin.
    Cancer Res. 1988 Apr 1;48(7):1722-6 PMID: 2832051
  43. Benzo[a]pyrene diol epoxide adducts in DNA are potent suppressors of a normal topoisomerase I cleavage site and powerful inducers of other topoisomerase I cleavages.
    Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2040-5 PMID: 10688881
Article Info
Journal
Proceedings of the National Academy of Sciences of the United States of America
Abbr.
Proc Natl Acad Sci U S A
ISSN
0027-8424
Published
2000-09-26
Pages
10739-44
Language
English
Region
United States
NLM ID
7505876
PMCID
PMC27093
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com